Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (NASDAQ: ILMN) is described by the company as a global leader in DNA sequencing and array-based technologies, serving research, clinical, and applied markets across genomics, multiomics, and proteomics. This news page aggregates recent press releases and announcements so readers can follow how Illumina’s technologies, collaborations, and financial disclosures evolve over time.
Company news highlights include product and platform launches, such as Illumina Connected Multiomics, a cloud-based software platform for analyzing and visualizing multiomic data, and Illumina Protein Prep, which the company states delivers broad coverage of the blood proteome and supports large-scale genomics studies. Illumina has also announced the Illumina Billion Cell Atlas, a large genome-wide genetic perturbation dataset developed through its BioInsight business to support AI-driven drug discovery in collaboration with pharmaceutical partners.
Investors can use this news feed to track Illumina’s preliminary financial results, earnings announcements, and capital markets activities, as reflected in press releases tied to quarterly and annual results and conference presentations. The page also captures updates on strategic agreements and acquisitions, including Illumina’s planned acquisition of Standard BioTools’ aptamer-based and functional proteomics business, as described in SEC filings and related communications.
In addition, Illumina’s news often covers leadership appointments, regulatory and market developments, and collaborations with genomics and population health partners such as MyOme. By reviewing these updates in one place, readers can better understand how Illumina positions its sequencing, multiomic, and proteomic offerings and how its corporate strategy and partnerships may influence its role in genomics and precision medicine. Bookmark this page to review new company-issued information as it becomes available.
Illumina (ILMN) reported Q4 2022 revenue of $1.08 billion, a 10% decrease from Q4 2021, and fiscal year revenue of $4.58 billion, up 1%. GAAP diluted loss per share was $(0.89) in Q4 2022 and $(28.00) for the full year. GRAIL segment recorded a significant goodwill impairment of $3.91 billion. Despite the challenges, the company anticipates 2023 revenue growth between 7% to 10% and expects GAAP diluted EPS of $0.03 to $0.28. CEO Francis deSouza emphasized strong customer interest in new products like the NovaSeq X and an increasing demand for GRAIL's Galleri test, with over 60,000 tests ordered to date.
Illumina marks World Cancer Day on February 4, 2023, by highlighting global efforts to close the cancer care gap. According to WHO, half of the world lacks access to essential health services, emphasizing the need for equitable cancer treatment. Illumina's chief medical officer, Phil Febbo, calls for improved access to treatments regardless of location. Various initiatives are showcased, including cancer screening outreach in Malaysia, educational tools in Brazil, advocacy for early detection in the US, and the establishment of precision oncology in Sweden. The company commends these organizations for their critical role in enhancing cancer care accessibility.
Illumina, Inc. (NASDAQ: ILMN) has appointed Joydeep Goswami as Chief Financial Officer, effective immediately. Previously serving as Chief Strategy and Corporate Development Officer and interim CFO since July 2022, Goswami's new role will involve overseeing financial planning, analysis, accounting, and investor relations. With over 20 years of experience in the life sciences industry, he aims to enhance shareholder value through improved financial operations. Francis deSouza, CEO of Illumina, expressed confidence in Goswami’s ability to drive growth, supported by a strong finance team.
Illumina participated as lead sponsor at the Festival of Genomics & Biodata 2023 in London, gathering over 4,000 experts from health care, academia, and technology. Key discussions included advancements in genomics and its impact on patient care. Notably, Illumina showcased its NovaSeq X series, highlighted as the most sustainable and powerful sequencer to date. The event emphasized the importance of genomics in transforming health care, with contributions from leaders from NHS England and Genomics England. Illumina's ongoing collaboration with the UK government aims to enhance the country's position in global genomics research.
Illumina Ventures announced the addition of two key members to its investment team: Abhijit “Ron” Mazumder as Partner and Lisa Alderson as Entrepreneur in Residence. Ron Mazumder brings nearly 30 years of experience in biomarkers and diagnostics from his previous roles at Genentech, Johnson & Johnson, and Merck. Lisa Alderson has over 25 years of experience in tech and healthcare, co-founding Genome Medical and holding executive positions at Invitae. These appointments aim to enhance the firm's ability to support innovation in genomics and precision medicine.
Illumina's Agricultural Greater Good Initiative Grant has been awarded to the Brazilian Consortium for Phycogenomics (BCP) for their project focused on Kappaphycus alvarezii, a vital seaweed for food security and sustainability. Announced at the Plant and Animal Genome conference, the grant will fund the generation of a high-quality genome sequence for this species, enhancing data for its cultivation. This initiative aims to improve small stakeholder outputs in Brazil, support sustainable practices, and contribute to carbon sequestration efforts globally, benefiting both environmental and agricultural sectors.
Summary not available.
Illumina, Inc. (NASDAQ:ILMN) announced it will release its fourth quarter and full year 2022 financial results on February 7, 2023, after market close. A conference call will follow at 2:00 PM PT to discuss these results, hosted by CEO Francis deSouza and Interim CFO Joydeep Goswami. Interested parties can access the call via Illumina's website or by phone. A replay will be available for 30 days post-event.
Illumina and Nashville Biosciences have partnered with Amgen to conduct whole-genome sequencing on approximately 35,000 DNA samples, primarily from African Americans, underrepresented in genomic research. This initiative marks a significant effort to enhance diversity in genomic data and accelerate therapeutic discovery. The project is part of a broader Alliance for Genomic Discovery, aiming to sequence a total of 250,000 samples. The sequencing will provide crucial insights for drug discovery and address health disparities, facilitating improved access to precision therapies.
GRAIL, LLC has launched an advanced research use only (RUO) targeted methylation-based technology for biopharmaceutical companies aimed at cancer signal interrogation through analyzing cell-free DNA. This solution facilitates prognosis, minimal residual disease detection, and monitoring of cancer recurrence. The technology boasts high analytical sensitivity and specificity, utilizing a blood-only liquid biopsy approach to improve the research process by circumventing issues related to tissue samples. GRAIL's RUO solution is now broadly available, having undergone successful early access trials with several partners.